Cargando…
The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT
Argatroban is a synthetic direct thrombin inhibitor with a relative short elimination half-life of 45 minutes and elimination which is predominantly performed via hepatic metabolism. Argatroban anticoagulation has been systematically studied in patients exhibiting the heparin-induced thrombocytopeni...
Autores principales: | Koster, Andreas, Fischer, Karl-Georg, Harder, Sebastian, Mertzlufft, Fritz |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721302/ https://www.ncbi.nlm.nih.gov/pubmed/19707320 |
Ejemplares similares
-
Argatroban for an alternative anticoagulant in HIT during ECMO
por: Rougé, Alain, et al.
Publicado: (2017) -
Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function
por: Yeh, Calvin H., et al.
Publicado: (2016) -
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19
por: Aliter, Kholoud F., et al.
Publicado: (2020) -
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS
por: Brückner, Lea, et al.
Publicado: (2021) -
Novel Monitoring and Dose Adjustment of Argatroban, a Direct Thrombin Inhibitor, to Maintain Therapeutic Anticoagulation in a Patient With Antiphospholipid Antibody Syndrome, Heparin-Induced Thrombocytopenia, and COVID-19 Pneumonia
por: Ryan, Christine E., et al.
Publicado: (2023)